“Multiplexed Viability, Cytotoxicity, and Caspase Activity Assays”

  • Andrew L. NilesEmail author
  • Terry L. Riss
Part of the Methods in Molecular Biology book series (MIMB, volume 1219)


Multiplexed assay chemistries provide for multiple measurements of cellular parameters within a single assay well. This experimental practice is not only more cost efficient, but also provides more information about a compound or treatment. The ability to combine the activity profiles within the same sample provides a level of normalization not possible with parallel assays. Furthermore, multiplexing caspase activity assays with viability and/or cytotoxicity assays can support conclusions regarding cytotoxic mechanism and provide normalization, which may help correct for differences in cell number.

Key words

Multiplex Fluorescence Luminescence Cell-based Cytotoxicity Caspase 


  1. 1.
    Grant S, Sklar J, Cummings R (2002) Development of novel assays for proteolytic enzymes using rhodamine-based substrates. J Biomol Screen 7:531–540PubMedCrossRefGoogle Scholar
  2. 2.
    Bronstein I, Fortin J, Stanley PE, Stewart GSAB, Kricka LJ (1994) Chemiluminescent and bioluminescent reporter gene assays. Anal Biochem 219:169–181PubMedCrossRefGoogle Scholar
  3. 3.
    Wesierska-Gadek J, Gueorguieva M, Ranftler C, Zerza-Schnitzhofer G (2005) A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death. J Cell Biochem 96:1–7PubMedCrossRefGoogle Scholar
  4. 4.
    Nieuwenhuijsen B, Huang Y, Wang Y, Ramerez F, Kalgaonkar G, Young K (2003) A dual luciferase multiplex high-throughput screening platform for protein-protein interactions. J Biomol Screen 8:676–684PubMedCrossRefGoogle Scholar
  5. 5.
  6. 6.
    Niles A, Worzella T, Zhou M, McDougall M, Lazar D (2012) Measuring cytotoxicity in real time with a highly stable green dye. [Internet] December 2012Google Scholar
  7. 7.
    Niles A, Moravec R, Riss T (2004) Characterizing responses to treatments using homogeneous caspase activity and cell viability assays. Cell Notes 9:11–14Google Scholar
  8. 8.
    Niles A, Worzela T, Scurria M, Daily W, Bernad L, Guthmiller P, McNamara B, Rashka K, Lange D, Riss T (2006) Multiplexed viability, cytotoxicity and apoptosis assays for cell-based screening. Cell Notes 16:12–15Google Scholar
  9. 9.
    Niles A, Moravec R, Riss T (2008) Update on in vitro cytotoxicity assays for drug development. Expert Opin Drug Discov 3:655–669PubMedCrossRefGoogle Scholar
  10. 10.
    Leist M, Jaattela M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Biol 2:1–10CrossRefGoogle Scholar
  11. 11.
    Worzella T et al (2013) Real-time cytotoxicity analysis using CellTox™ green cytotoxicity assay and the Tecan Infinite® 200 PRO with gas control module. [Internet] May 2013Google Scholar
  12. 12.
    Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13:7–26PubMedCrossRefGoogle Scholar
  13. 13.
    Hook B, Bratz M, Schagat T (2013) Gain more informative data by multiplexing a fluorescent real-time cytotoxicity assay with luminescent, fluorescent or colorimetric viability assays. [Internet] June 2013Google Scholar
  14. 14.
    Niles A, Moravec R, Hesselberth P, Scurria M, Daily W, Riss T (2007) A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal Biochem 366:197–206PubMedCrossRefGoogle Scholar
  15. 15.
    Riss T, Moravec R (2004) Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based assays. Assay Drug Dev Technol 2:51–62PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Promega CorporationMadisonUSA

Personalised recommendations